Innovent Biologics, Inc.
HKEX:1801.HK
35.05 (HKD) • At close November 1, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) HKD.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|
| Revenue
| 6,206.07 | 4,556.38 | 4,269.729 | 3,843.819 | 1,047.525 | 9.477 | 18.538 | 32.127 |
| Cost of Revenue
| 1,136.266 | 930.99 | 573.04 | 387.761 | 124.878 | -1.312 | -71.472 | 0 |
| Gross Profit
| 5,069.804 | 3,625.39 | 3,696.689 | 3,456.058 | 922.647 | 10.789 | 90.01 | 32.127 |
| Gross Profit Ratio
| 0.817 | 0.796 | 0.866 | 0.899 | 0.881 | 1.138 | 4.855 | 1 |
| Reseach & Development Expenses
| 2,227.556 | 2,871.22 | 2,478.067 | 1,851.453 | 1,294.724 | 1,221.687 | 611.922 | 384.653 |
| General & Administrative Expenses
| 750.278 | 835.488 | 884.027 | 436.872 | 255.299 | 277.502 | 87.768 | 57.38 |
| Selling & Marketing Expenses
| 3,100.693 | 2,590.765 | 2,728.166 | 1,340.861 | 1,192.24 | 136.006 | 9.94 | 5.031 |
| SG&A
| 3,850.971 | 3,426.253 | 3,612.193 | 1,777.733 | 1,447.539 | 413.508 | 87.768 | 57.38 |
| Other Expenses
| -680.093 | -90.198 | -45.126 | -130.685 | -41.381 | -4,338.044 | -51.013 | -123.197 |
| Operating Expenses
| 5,979.014 | 6,207.275 | 6,045.134 | 3,498.501 | 2,700.882 | 1,562.078 | 643.266 | 413.266 |
| Operating Income
| -1,679.301 | -2,073.933 | -3,112.859 | -820.139 | -1,663.087 | -1,785.633 | -750.136 | -461.538 |
| Operating Income Ratio
| -0.271 | -0.455 | -0.729 | -0.213 | -1.588 | -188.418 | -40.465 | -14.366 |
| Total Other Income Expenses Net
| 534.89 | -96.536 | 61.844 | -38.574 | -56.863 | -4,900.234 | -109.654 | -146.514 |
| Income Before Tax
| -1,144.411 | -2,170.469 | -3,051.015 | -858.713 | -1,719.95 | -5,872.982 | -716.05 | -544.456 |
| Income Before Tax Ratio
| -0.184 | -0.476 | -0.715 | -0.223 | -1.642 | -619.709 | -38.626 | -16.947 |
| Income Tax Expense
| -116.498 | 8.801 | 87.038 | 139.708 | 56.863 | 27.479 | -244.365 | -150.969 |
| Net Income
| -1,027.913 | -2,179.27 | -3,138.053 | -998.421 | -1,776.813 | -5,771.492 | -562.318 | -504.204 |
| Net Income Ratio
| -0.166 | -0.478 | -0.735 | -0.26 | -1.696 | -609 | -30.333 | -15.694 |
| EPS
| -0.66 | -1.46 | -2.16 | -0.74 | -1.51 | -17.24 | -0.5 | -0.45 |
| EPS Diluted
| -0.66 | -1.46 | -2.16 | -0.74 | -1.51 | -17.24 | -0.5 | -0.45 |
| EBITDA
| -690.539 | -1,754.511 | -2,908.112 | -734.512 | -1,576.72 | -5,741.776 | -635.928 | -454.064 |
| EBITDA Ratio
| -0.111 | -0.385 | -0.681 | -0.191 | -1.505 | -605.864 | -34.304 | -14.133 |